Press Releases Events & Presentations Press Releases Year None2022202120202019201820172016201520142013201220112010 Nov 14, 2022 Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334 View HTML PDF Version Nov 08, 2022 Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation View HTML PDF Version Nov 04, 2022 Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV View HTML PDF Version Oct 24, 2022 Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting® View HTML PDF Version Oct 05, 2022 Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A. Okazaki as Successor View HTML PDF Version Aug 24, 2022 Assembly Biosciences to Host Webcast on August 31, 2022, Introducing Two New Research Programs Targeting Recurrent HSV-2 Infection and Transplant-Associated Herpesvirus Diseases View HTML PDF Version Aug 09, 2022 Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights View HTML PDF Version Jul 20, 2022 Assembly Biosciences Announces Program Reprioritization and Organizational Update View HTML PDF Version Jun 22, 2022 Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL’s International Liver Congress™ 2022 View HTML PDF Version Jun 21, 2022 Assembly Biosciences to Introduce New Small Molecule Liver-Focused Interferon-α Receptor Agonist Research Program in Webcast on July 26, 2022 View HTML PDF Version Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Shareholder Tools Print Email Alerts Printed Materials RSS News Feeds Search Investors
Press Releases Year None2022202120202019201820172016201520142013201220112010 Nov 14, 2022 Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334 View HTML PDF Version Nov 08, 2022 Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation View HTML PDF Version Nov 04, 2022 Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV View HTML PDF Version Oct 24, 2022 Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting® View HTML PDF Version Oct 05, 2022 Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A. Okazaki as Successor View HTML PDF Version Aug 24, 2022 Assembly Biosciences to Host Webcast on August 31, 2022, Introducing Two New Research Programs Targeting Recurrent HSV-2 Infection and Transplant-Associated Herpesvirus Diseases View HTML PDF Version Aug 09, 2022 Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights View HTML PDF Version Jul 20, 2022 Assembly Biosciences Announces Program Reprioritization and Organizational Update View HTML PDF Version Jun 22, 2022 Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL’s International Liver Congress™ 2022 View HTML PDF Version Jun 21, 2022 Assembly Biosciences to Introduce New Small Molecule Liver-Focused Interferon-α Receptor Agonist Research Program in Webcast on July 26, 2022 View HTML PDF Version Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »
